Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-Hodgkin's lymphomas: current classification and management

A T Skarin1, D M Dorfman

  • 1Adult Oncology Department, Dana-Farber/Partners Cancer Care, Boston, MA, USA.

CA: a Cancer Journal for Clinicians
|November 26, 1997
PubMed
Summary

Advances in non-Hodgkin's lymphoma classification and immunology have refined treatment strategies. Early-stage indolent lymphomas are treated with radiotherapy, while advanced and aggressive types require combination chemotherapy or leukemia-like regimens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory pseudotumor of lymph node and spleen: an entity biologically distinct from inflammatory myofibroblastic tumor.

Human pathology·2002
Same author

Splendore-Hoeppli phenomenon.

Archives of pathology & laboratory medicine·2001
Same author

Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial.

Cancer chemotherapy and pharmacology·2001
Same author

Phenotypic characterization of subsets of T cell lymphoma: towards a functional classification of T cell lymphoma.

Leukemia & lymphoma·2001
Same author

Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer.

Anticancer research·2001
Same author

Lung cancer in patients under age 40.

Lung cancer (Amsterdam, Netherlands)·2001

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Significant advancements in non-Hodgkin's lymphoma (NHL) classification over the last 15 years.
  • Monoclonal antibodies targeting cell surface antigens have enhanced understanding of NHL immunology.

Purpose of the Study:

  • To summarize the progress in NHL classification and treatment strategies.
  • To highlight the role of immunological understanding in disease management.

Main Methods:

  • Review of classification systems for non-Hodgkin's lymphomas.
  • Analysis of treatment approaches based on disease stage and aggressiveness.
  • Integration of immunological insights from monoclonal antibody studies.

Main Results:

Related Experiment Videos

  • Refined classification of NHL has improved diagnostic accuracy.
  • Treatment protocols are stratified by indolent versus aggressive lymphoma subtypes.
  • Immunological markers guide therapeutic decisions and prognostication.

Conclusions:

  • Modern classification and immunological insights have transformed NHL management.
  • Tailored treatment strategies, including radiotherapy and chemotherapy, improve patient outcomes.
  • Further research into NHL immunology will likely yield more targeted therapies.